Spontaneous Hemopericardium as an Adverse Effect of Rivaroxaban Administration

Asif Surani, MD*, Beatriz Martinez Quintero, MD, David Brual, MD, Hadi Elias, MD, Fahad Uddin Ahmed, MD and Matthew Peters, MD
Saint Agnes Hospital, 900 S Caton Ave, Baltimore, 21229, Maryland, USA

*Corresponding author: Asif Surani, MD, Saint Agnes Hospital, 3300 S Stonegate Circle, Apt 208, New Berlin, WI 53151, USA, Tel: 6672146641

Abstract
Rivaroxaban is a direct oral anticoagulant with a favorable safety profile when compared to warfarin in respect to bleeding. During post-marketing surveillance, intracranial and retroperitoneal bleedings have been reported; however, hemopericardium has not been frequently described. In this case series, we present three cases of spontaneous hemopericardium where rivaroxaban was thought to be the causative agent. Predisposing factors for rivaroxaban induced hemopericardium might include impaired kidney function, concomitant use of antiplatelet agents, herbal supplements, and CYP3A4 metabolizers and inhibitors. Clinicians should be aware of the possibility of such life-threatening adverse event in patients taking rivaroxaban and should consider it in their differential diagnosis in a patient presenting with chest pain and/or dyspnea while on rivaroxaban. This case series suggests that rivaroxaban induced hemopericardium might not be as rare as initially thought.

Introduction
Rivaroxaban, a factor Xa inhibitor, has been approved by the Food and Drug Administration (FDA) to be used as an anticoagulant in multiple medical conditions, such as deep venous thrombosis (DVT), DVT prophylaxis after knee and hip replacement, prevention of thromboembolism in nonvalvular atrial fibrillation, and pulmonary embolism. In recent years, several studies, including a meta-analysis of rivaroxaban and bleeding risks when compared to vitamin K antagonists, have shown that rivaroxaban has a favorable bleeding-related safety profile with a decrease in fatal bleeding, no suggestion of an increase in all-cause mortality, and no statistical significant difference when compared to vitamin K antagonists in the proportion of major and clinically relevant non-major bleeding [1]. Nonetheless, major bleeding events have been reported, including intracranial hemorrhage, gastrointestinal bleeding, retroperitoneal bleeding, and intraocular bleeding [2]. Yet, there is less than a handful of case reports describing spontaneous hemopericardium after administration of rivaroxaban [3-9]. We present a case series including three patients presenting with isolated spontaneous hemopericardium while receiving rivaroxaban.

Case Report

Case 1

A 66-year-old African American male with a past medical history of hypertension, type 2 DM, peripheral vascular disease status post right above knee amputation, and recent DVT on rivaroxaban presented with persistent chest pain for two weeks duration. The pain was worsened with lying down and taking deep inspiratory breaths, and was relieved slightly by bending forward. It was associated with dyspnea, diaphoresis, subjective fevers, decreased appetite and generalized weakness. His medications included rivaroxaban 20 mg daily, gabapentin, glipizide, and losartan. Of note, the patient was admitted with similar chest pain ten days prior; workup at that time revealed ST elevation in anterolateral leads, however his cardiac catheterization and echocardiogram (ECHO) were unremarkable. On physical exam he was febrile with a temperature of 103.2°F and tachycardic. Other significant findings included distant heart sounds, weak peripheral pulses, and pul-
the patient was discharged on colchicine and prednisone. Anticoagulation was held on discharge as the patient had already completed a six month course of anticoagulation for his provoked DVT with repeat negative doppler ultrasound results. Follow up ECHO one month post discharge revealed complete resolution of his pericardial effusion.

**Case 2**

A 65-year-old female from Ghana origin with a past medical history of non-ischemic cardiomyopathy and an EF of 25%, hypertension, type 2 DM, chronic atrial fibrillation, and history of left atrial appendage thrombus (on rivaroxaban for > 2-years) presented with complaints of dyspnea and chest pressure. The dyspnea started two weeks prior to presentation, was non-exertional, and accompanied by chest pressure. Her medication history was significant for rivaroxaban 20 mg daily, metoprolol, losartan, sitagliptin, metformin, and atorvastatin.

Her vital signs were unremarkable except for hypertension. Pertinent physical exam findings included jugular venous distention, irregularly irregular pulse, absence of pulsus paradoxus and normal heart sounds. Her BMI was 30. Initial CBC and BMP were unremarkable with normal kidney and liver functions. Her troponins were normal, and BNP was elevated at 1570 pg/mL. Her INR was 1.4 and a PTT was 31 seconds. CXR showed stable cardiomegaly. Her ECG revealed atrial fibrillation.

**Figure 1:** Echocardiogram demonstrating the large circumferential pericardial effusion in A) Apical four chamber view; B) Parasternal short axis view; C) Subcostal four chamber view.
Fatigue for two days. Her past medical history was also significant for renal cancer s/p right sided nephrectomy, sub-centimeter lung nodules, and cervical cancer s/p total abdominal hysterectomy. Her medications included rivaroxaban 7.5 mg daily (she was started on low dose rivaroxaban due to being underweight and episodes of bruising while on full dose of anticoagulation), clopidogrel, lisinopril, amlodipine, carvedilol, tramadol, lorazepam PRN, vicodin PRN and famotidine. Upon arrival, she was hemodynamically unstable with persistent hypotension. She was minimally responsive to fluids and required vasopressor support. Her physical exam was pertinent for distant heart sounds, negative jugular venous distention, and clear lungs. Pulsus paradoxus was not assessed. Her BMI was 16. Initial blood work revealed Hb of 8.1 g/dl, leukocytosis 12.5 K/microL with predominant neutrophils, acute renal failure with Cr. of 2.2 mg/dl (baseline 0.6 mg/dl), CRP 64.2 mg/l, and negative troponins. Coagulation profile was unfortunately not obtained on admission. She had a CXR which revealed enlarged cardiac silhouette which was a significant change compared to a CXR done 2 weeks prior. Point of care ultrasound was obtained at the bedside which revealed a large circumferential effusion (Figure 3). The patient was managed as a case of cardiac tamponade and was taken to the cardiac catheterization lab where she underwent emergent pericardiocentesis with drainage of a substantial amount of hemorrhagic fluid (the amount was not documented). Unfortunately, the procedure was complicated by right ventricular puncture with about 500-600 cc of blood loss and subsequent pulseless ventricular tachycardia requiring 2 minutes of CPR with ROSC. The patient required endo-

Figure 2: Echocardiogram demonstrating the circumferential pericardial effusion in A) Parasternal long axis view; B) Apical four chamber view; C) Subcostal four chamber view; D) Parasternal short axis view.
Patients in case 1 and 2 were taking full strength rivaroxaban 20 mg daily with duration of more than nine months and two years respectively. However, the patient in case 3 was on low dose rivaroxaban 7.5 mg daily for five months. Only case 3 was on concomitant antiplatelet agent i.e. clopidogrel. In addition, it should be noted that case 1 had concomitant pericarditis and underwent an uncomplicated cardiac catheterization without PCI one week ago. The cardiac catheterization for case 3 was done five months ago during which two drug eluting stents were deployed. We do not think that there was a traumatic tap in case 3 and procedural complication occurred after pericardiocentesis was performed.

Rivaroxaban has been FDA approved since 2011. It is popular among clinicians due to lack of frequent blood monitoring, once daily dosing, and few drug interactions. With its widespread use, there have been multiple case reports of unusual bleeding events including hemopericardium, which were not identified in meta-analyses and post-marketing experience [1,2]. To our knowledge, the first case of spontaneous hemopericardium was reported in 2014 [3], and since then few other cases have been reported

**Figure 3**: Echocardiogram demonstrating the large circumferential pericardial effusion in A) Off axis parasternal long axis view; B,C) Subcostal four chamber view during inspiration and expiration.
[5-9]. There are two case reports of rivaroxaban induced hemopericardium in setting of acute pericarditis which were similar to our case 4,5. None of the published case reports in the literature have recent cardiac catheterization done as seen in our first case.

Review of these published case reports also highlight various risk factors that could have contributed in the development of hemopericardium. Concomitant use of saw palmetto and in vitro inhibitor of CYP3A4 have been implicated in the case report published by Shivamurthy, et al. [3]. Renal insufficiency and simultaneous use of azithromycin was attributed by Boone S in his case report [4]. Menedez, et al. suspected co-administration of multiple drugs metabolized by CYP3A4 (including omeprazole, atorvastatin, dronedarone, tamsulosin, and tadalafil) as the causative factor for hemopericardium [7]. Similarly, renal insufficiency and concurrent use of amiodarone (an inhibitor of CYP3A4 and P-glycoprotein) was considered by Oladiran, et al. [9]. Also, the combined use of aspirin and rivaroxaban was seen in only two reported cases [4,5]. Compared to these published cases, our case series has identified acute renal insufficiency, concomitant use of clopidogrel and rivaroxaban, and recent cardiac catheterization as potential risk factors. The presence of CYP3A4 substrates were seen in case 2 (atorvastatin) and case 3 (lorazepam, vicodin and tramadol). However, it should be noted that in case 2 there was no report of multiple CYP3A4 drugs other than atorvastatin, and use of opiates and benzodiazepine was only as PRN in case 3. Thus, it is unclear if this mechanism has played a significant role in our case series.

Other anticoagulants including warfarin, apixaban and dabigatran have also been associated with hemopericardium [3,11,12]. Considering the frequent use of these novel anticoagulants and possible association with spontaneous hemopericardium as mentioned in our case series and other published case reports, an early ECHO seems to be a reasonable test for evaluation of pericardial effusion in a patient presenting with chest pain and dyspnea while on these agents in an appropriate clinical setting. Prescribers should be attentive to various factors as mentioned above that can enhance the anticoagulant effects of these agents and lead to spontaneous hemorrhage. As of 2018, andexanet alfa has been FDA approved for reversal of factor Xa inhibitors in a major life-threatening hemorrhage associated with anti-factor Xa medications [13], however, its limited availability and lack of consensus guidelines limits its widespread use. In conclusion, we present a case series of hemorrhagic pericardial effusion likely related to rivaroxaban use. Clinicians should be aware about this potential adverse effect of rivaroxaban and consider hemorrhagic pericardial effusion as a differential in patient presenting with dyspnea and chest pain in an appropriate clinical setting. Early recognition by an echocardiogram and prompt treatment can prevent serious life-threatening complications.

Conflict of Interest
The authors declare that there is no conflict of interest regarding the publication of this article.

Authors Contribution
All authors have contributed equally to this manuscript.

References